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Passiflora incarnata is marketed in many countries as a phytomedicine. Even though the directions of 
most marketed phytomedicines recommend them to be used under medical supervision, reproductive 
and developmental studies are sparse and not mandatory for regulatory purposes. In this study, a 
reproductive toxicity evaluation of P. incarnata was conducted in Wistar rats gavaged (30 or 300 mg/kg) 
during pregnancy and lactation. Moreover, considering that antioxidant properties have been attributed 
to flavonoids present in the genus Passiflora, it was also evaluated the antioxidant/pro-oxidant balance 
in the plasma of these dams and the antioxidant potential in an in vitro test. P. incarnata treatment did 
not influence dams´ body weight as well as reproductive (gestation length, post-implantation loss, litter 
size, litter weight) and hepatic (albumin, AST, ALT, GGT) parameters. The antioxidant property of P. 
incarnata was evidenced both in vivo (increase in the total antioxidant plasmatic potential) and in vitro 
(decrease in neutrophil-induced respiratory burst). The results from the present study indicate that under 
the experimental conditions evaluated, P. incarnata treatment during gestation and lactation presented 
antioxidant activity in the absence of maternal reproductive toxicity.
Uniterms: Phytomedicines/evaluation. Passiflora incarnata/use in pregnancy. Passiflora incarnata/
use in lactation. Passiflora incarnata/reproductive toxicity/experimental study. Pregnancy/use of 
phytomedicines. Lactation/use of phytomedicines. Oxidative stress.
Passiflora incarnata é comercializada em muitos países como fitoterápico. Embora a bula da maioria 
dos fitoterápicos recomende que eles sejam usados sob supervisão médica, estudos sobre a toxicidade 
reprodutiva e do desenvolvimento desses produtos são raros e não obrigatórios para fins regulatórios. 
Neste estudo, realizamos uma avaliação da toxicidade reprodutiva da P. incarnata, administrada a 
ratas Wistar (30 ou 300 mg/kg, gavagem) durante a gestação e a lactação. Além disso, considerando 
as propriedades antioxidantes que têm sido atribuídas aos flavonoides presentes no gênero Passiflora, 
também avaliou-se o equilíbrio antioxidante/pró-oxidante no plasma destas fêmeas e conduziu-se um 
teste in vitro para avaliar o potencial antioxidante. O tratamento com P. incarnata não influenciou o peso 
corporal das fêmeas, bem como indicadores de toxicidade reprodutiva (perdas pós-implantação, número 
de filhotes vivos e peso da ninhada) e os parâmetros de função hepática (albumina, AST, ALT, GGT). A 
propriedade antioxidante da P. incarnata foi evidenciada tanto in vivo (aumento do potencial antioxidante 
total plasmático) quanto in vitro (diminuição do burst respiratório em neutrófilos). Os resultados deste 
estudo indicam que, nas condições experimentais avaliadas, o tratamento com P. incarnata durante 
a gestação e lactação apresentou efeito antioxidante, na ausência de toxicidade reprodutiva materna.
Unitermos: Fitoterápicos/avaliação. Passiflora incarnata/uso na gestação. Passiflora incarnata/uso 
na amamentação. Passiflora incarnata/toxicidade reprodutiva/estudo experimental. Gestação/uso de 
fitoterápicos. Lactação/uso de fitoterápicos. Estresse oxidativo.
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INTRODUCTION
Herbal medicine products (HMP) have been used 
worldwide (Yunes, Calixto, 2001; Buttar, Jones, 2003; 
Koren et al., 2008). The belief on the safety of natural 
products (Buttar, Jones, 2003) makes HMPs appealing 
for some populational groups including children, pregnant 
women and the elderly.
Passiflora incarnata is marketed in many countries 
as an anxiolytic and sedative phytomedicine (Soulimani 
et al., 1997; Zanoli, Avallone, Baraldi, 2000) and 
its mechanism of action involves potentiation of the 
GABAergic system (Zanoli, Avallone, Baraldi, 2000; 
Grundmann et al., 2008). As observed for many HMP used 
by the population, information regarding the safety of P. 
incarnata use during pregnancy and/or lactation is sparse 
(Veríssimo et al., 2011). To the best of our knowledge, only 
one study suggested, in vitro, an uterotonic action of this 
plant (Ruggy, Smith, 1940). Based on this study, the labels 
of P. incarnata-based phytomedicines marketed in Brazil 
indicate that its use during pregnancy and/or breastfeeding 
needs physician or dentist supervision (Brasil, 2008). 
However, advising without scientific support certainly is 
not an easy task for these professionals.
This study was designed to investigate if P. incarnata 
induces maternal toxicity when administered to Wistar rats 
during pregnancy and lactation. Moreover, considering 
that antioxidant properties have been attributed to 
flavonoids present in the genus Passiflora (Rudnicki et 
al., 2007; Masteikova et al., 2008), it was also evaluated 
the antioxidant/pro-oxidant balance in the plasma of these 
dams as well as P. incarnata antioxidant potential through 
an in vitro test.
MATERIAL AND METHODS
Animals and treatment
Male and female wistar rats (75-90 days) from the 
colony of the State University of Londrina (UEL) were 
mated (2 or 3 females and 1 male per cage) overnight and 
gestational day (GD) 0 was considered if there were sperm 
and estrus phase cells in vaginal smears.
Pregnant rats were housed singly and randomly 
divided into control- or P. incarnata-treated dams. Control 
dams (Con: 15 dams) were gavaged daily with tap water 
whereas P. incarnata were gavaged with 30 (P30: 17 
dams) or 300 (P300: 14 dams) mg/kg. Treatment lasted 
from GD 0 to lactational day (LD) 21 and doses were daily 
adjusted according to weight. A HMP marketed in Brazil 
(Passiene™, Herbarium Laboratories) was employed as 
the source of P. incarnata. This syrup is standardized in 
0.19% of vitexin. In humans, the dose of 20-30 mg/kg/day 
is usually recommended.
All animals had free access to water and regular lab 
chow (Nuvital™). They were maintained in the vivarium 
of the Department of Physiological Sciences at 21±2 °C 
on a 12:12h light-dark cycle (on at 0700). All animal 
procedures were approved by the UEL Ethics Committee 
for Animal Research (CEEA 16/2010).
Maternal toxicity and reproductive performance 
of dams
Maternal body weight was measured daily during 
gestation and lactation. Furthermore, the corrected 
maternal body weight gain was estimated subtracting the 
weight on GD 0 from the weight on LD 0. On LD 0, the 
number of pups in each litter was determined as well as 
the litter weight. On LD 21, dams were submitted to an 
open-field in order to evaluate general activity (Bacchi et 
al., 2013). They were euthanized with diethyl ether and 
their livers were dissected and weighed. The uterine horns 
were also dissected and the numbers of implantation sites 
were counted to determine the rate of postimplantation 
loss [(number of implantations–number of live fetuses/
number of implantations)x100]. Blood was collected 
through cardiac puncture and centrifuged at 1000 g for 
15 minutes. Plasma was aliquoted and stored at -70 ºC 
for subsequent laboratory testing. Hepatic function was 
evaluated through the determination of gamma-glutamyl 
transferase (GGT), aspartate aminotransferase (AST), 
alanine aminotransferase (ALT), albumin and total 
proteins. GGT, ALT and AST were analyzed using UV-
kinetic methods in an automated biochemical system 
(Dimension® RXL, Deerfield, IL, USA). Albumin and total 
protein were measured through the use of colorimetric 
commercial kits (Ebram™, Brazil).
Plasmatic antioxidant/pro-oxidant balance
Total serum antioxidant potential (TRAP) was 
determined by chemiluminescence using an adaptation 
from the method described by Repetto et al. (1996). 
This experiment was conducted in a Beckman b counter, 
model LS 6000 (Fullerton, CA, USA) in a non-coincident 
counting mode for 25 minutes and with a response range 
between 300 and 620 nm. The system was calibrated 
with vitamin E analogue (Trolox). A comparison of the 
induction time after the addition of known concentrations 
of Trolox and plasma allows obtaining TRAP values of 
Trolox equivalents.
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Pro-oxidant markers evaluated in this work were lipid 
hydroperoxides, malondialdehyde (MDA), products of 
advanced protein oxidation (AOPP) and nitric oxide (NO).
Lip id  hydroperox ides  were  measured  by 
spectrophotometry (FOX) using an adaptation of the 
technique described by Jiang, Woollard, Wolff (1991). 
The method is based on the oxidation of ferrous to ferric 
ions by peroxide under acidic conditions, which reacts 
with the indicator dye (xylenol orange) and produces 
a colored complex. The system was calibrated with a 
standard solution of 1,1,3,3-tetraethoxyproprane. The 
reading was performed in a spectrophotometer (Helios 
α ThermoSpectronic ™, Waltham, MA, USA) at a 
wavelength of 560 nm and the results are expressed in mM.
MDA, which results from the decomposition of 
hydroperoxides, was quantified by high performance 
liquid chromatography using an adaptation of the 
technique described by Bastos et al. (2012). Results are 
expressed in nM/mg of protein.
AOPP was quantified by the method described by 
Witko-Sarsat et al. (1998). The method is based on the 
reaction of oxidized proteins with potassium iodide in 
acid conditions. The calibration curve was obtained from 
a stock solution of 1mM chloramine and the absorbance 
of the reaction was determined spectrophotometrically 
(Helios α ThermoSpectronic®, Waltham, MA, USA) at 
340 nm. AOPP concentrations are expressed in μM/L 
equivalent of chloramine.
NO levels were assessed indirectly by determining 
the plasma concentration of nitrite, using an adaptation 
of the technique described by Navarro-Gonzalez, Garcia-
Benayas and Arenas (1998). The quantification of nitric 
oxide was made in a microplate reader (Biochrom ASYS 
Expert Plus™, Holliston, MA, USA) at a wavelength of 
550nm. The results are expressed in µM/L.
In vitro evaluation of the antioxidant activity of P. 
incarnata
The reactive oxygen species (ROS) production 
by neutrophils (respiratory burst) was evaluted by 
chemiluminescence according to an adaptation of the 
method described by Freitas et al. (2008) and Huber, 
Krötz-Fahning, Hock (2006) in a multiplate reader (Victor 
X3, Perkin Elmer, USA). Human neutrophils were isolated 
from whole blood through gradient density centrifugation. 
Neutrophil burst was induced by phorbol myristate acetate 
(PMA) in the presence of 5 or 10 µL of P. incarnata syrup 
(75 mg/mL) or vehicle (base syrup). The detection probe 
was luminol. Kinetic readings were initiated immediately 
after cell stimulation and measured each other minute for 
60 minutes. Effects are expressed as chemiluminescence 
arbitrary units (cpm). For each experimental group, 8-10 
replicates were conducted. For statistical analysis, the 
peak value of each curve was used, independently of the 
time it occurred.
Statistical analysis
Initially, an exploratory analysis was conducted 
to evaluate normal distribution (Shapiro-Wilk test) and 
homogeneity of variance (Levene test) of each variable. 
For variables that presented normal distribution and 
homogeneity of variance, parametric analysis were 
conducted. Due to the high number of dams employed 
in this study, they could not be treated all at once and 
our sample is composed from animals belonging to two 
different cohorts. Because of this, cohort was added as a 
factor in the statistical analysis. The parametric statistical 
tests employed in this study were:
·	 Two-way ANOVA (factors: cohort, treatment) 
complemented with Bonferroni: corrected maternal 
body weight gain, litter size, litter weight, postim-
plantation loss, liver weight, open-field behaviors 
(ambulation, rearing), biochemical parameters 
(except AST);
·	 Two-way Repeated Measures ANOVA (RMANO-
VA) complemented with Bonferroni: weight gain of 
dams;
·	 Two-way ANCOVA complemented with Bonferroni: 
liver weight (weight on LD 21 was the covariate).
Grooming behavior evaluated in the open-field, AST 
and data from respiratory burst did not present normal 
distribution and/or homogeneity of variance and were 
analyzed through the non-parametric test of Kruskal-
Wallis complemented with Dunn. Differences were 
considered significant if p<0.05.
RESULTS
Maternal toxicity and reproductive performance 
of dams
Gestation length was not influenced by Passiflora 
treatment and no clinical signs of toxicity were observed 
during the daily treatment. RMANOVA indicated an effect 
of the day on dams’ weight [F(3,111)=651.9, p<0.0001] 
reflecting the fluctuations that occur during pregnancy and 
lactation (data not shown). P. incarnata treatment did not 
influence (p>0.05) weight gain as well as the corrected 
weight gain of dams during gestation (weight in LD 0 – 
weight in GD 0). Means and SEM for the corrected weight 
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gain were Con=32.7±4.2 (n=15); P30=25.9±3.2 (n=17); 
P300=22.6±2.8 (n=14). Two-way ANOVA showed that 
P. incarnata treatment did not influence (p>0.05) the 
number of uterine implantation sites, post-implantation 
loss, number of pups per litter and weight of pups at birth 
(Table I). Dead pups at birth were observed in 2 Con 
litters and in 2 P300 litters. No macroscopic alteration was 
observed during necropsy.
P. incarnata treatment did not influence (p>0.05) 
any of the behaviors evaluated in the open-field (Table I) 
as well as biochemical markers of hepatic function (Table 
II) and liver weight (Con=14.4±0.4; P30=13.8±0.3, 
P300=14.7±1.2).
In vivo evaluation of the antioxidant activity of P. 
incarnata
Data from the antioxidant/pro-oxidant plasmatic 
balance in dams are presented in Table III. Two-way 
ANOVA indicated that P. incarnata treatment influenced 
TRAP levels [F(2,42)=5.1, p<0.05]. Bonferroni post-hoc 
test revealed that, compared to CON, P30 tended (p=0.06) 
to increase TRAP and P300 significantly increased it 
(p<0.05). Even though total plasmatic antioxidant capacity 
was increased in P. incarnata-treated dams, a significant 
difference in the levels of the pro-oxidant markers 
evaluated (lipid hydroperoxides, MDA, AOPP and NO) 
was not detected (Two-way ANOVA, p>0.05).
In vitro evaluation of the antioxidant activity of P. 
incarnata
Figure 1A presents the chemiluminescence produced 
by PMA-stimulated neutrophils in the absence (Control) 
or presence of 5 and 10 µL of P. incarnata syrup (75 mg/
mL) or vehicle (10 µL of base syrup). Each curve is the 
mean of 8-10 replicates.
Kruskall-Wallis indicated a significant difference in 
the peak values of the kinetic curves (H=30.1, p<0.0001). 
Dunn´s test revealed that the peak values obtained with 
both volumes of P. incarnata syrup (5 and10µL) were 
different from control and vehicle (Figure 1B).
TABLE I - Reproductive parameters and general activity in the open-field of dams treated with P. incarnata during gestation and 
lactation
Con 
(n=15)
P30 
(n=17)
P300 
(n=14)
REPRODUCTIVE PARAMETERS
Live pups (count) 11.6 ± 0.4 11.2 ± 0.9 11.4 ± 0.6
Post-implantation loss (%)a 6.1 ± 1.9 4.2 ± 1.8 10.0 ± 3.8
Mean pups weight (g)b 5.8 ± 0.1 6.1 ± 0.2 6.1 ± 0.2
GENERAL ACTIVITY
Ambulation (count) 40.9 ± 2.7 44.0 ± 2.2 39.9 ± 2.4
Rearing (count) 22.9 ± 2.0 21.7 ± 1.5 18.9 ± 2.3
Grooming (seconds) 8.4 (5.0–13.9) 8.5 (4.2-30.0) 17.4 (0.9-40.1) #
Except for grooming, data are means ± SEM and were analyzed by two-way ANOVA (factors: cohort and treatment). Grooming is 
presented as median (minimum-maximum values) and was analyzed by the non-parametric test of Kruskal-Wallis complemented 
with Dunn. # p<0.05 compared to P30. Con: distilled water; P30: P. incarnata 30 mg/kg; P300: P. incarnata 300 mg/kg. a(Number 
of uterine implantation sites – number of live fetuses/number of implantations) x 100. bTotal weight of the litter divided by the 
total number of the pups on GD 0.
TABLE II - Plasmatic parameters of hepatic function in dams treated with P. incarnata during gestation and lactation
Con P30 P300
Total proteins (g/dL) 6.0 ± 0.2 (n=15) 5.8 ± 0.2 (n=17) 5.8 ± 0.1 (n=14)
Albumin (g/dL) 2.9 ± 0.1 (n=15) 3.0 ± 0.1 (n=16) 3.1 ± 0.1 (n=13)
GGT (IU/L) 3.3 ± 0.3 (n=15) 2.6 ± 0.4 (n=16) 2.5 ± 0.4 (n=12)
ALT (IU/L) 159.6 ± 6.7 (n=15) 148.8 ± 7.4 (n=16) 152.2 ± 10.8 (n=12)
AST (IU/L) 140.0 (104.0–165.0) (n=15) 130.0 (105.0-215.0) (n=16) 127.0 (110.0-143.0) (n=12)
Total proteins, albumin, GGT and ALT are presented as means ± SEM and were analyzed by two-way ANOVA (p>0.05). AST is 
presented as median (minimum-maximum) and was analyzed by the non-parametric test of Kruskal-Wallis (p>0.05). Con: distilled 
water; P30: P. incarnata 30 mg/kg; P300: P. incarnata 300 mg/kg.
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TABLE III - Plasmatic oxidative stress parameters in dams treated with P. incarnata during gestation and lactation
Con P30 P300
AOPP (μmoles/L equivalent of 
chloramine)
144.9 ± 9.5 (n=15) 149.7 ± 9.3 (n=17) 154.1 ± 10.9 (n=14)
LOOH (mM) 0.83 ± 0.05 (n=15) 0.81 ± 0.05 (n=17) 0.74 ± 0.07 (n=14)
MDA (ng/mg of protein) 69.2 ± 4.1 (n=13) 76.2 ± 5.1 (n=15) 75.8 ± 5.1 (n=13)
NO (μM/L) 4.1 ± 0.8 (n=15) 3.9 ± 0.5 (n=16) 5.1 ± 0.7 (n=13)
TRAP (Trolox equivalents) 381.4 ± 12.9 (n=14) 436.4 ± 16.1& (n=15) 450.9 ± 19.0* (n=14)
The results are presented as means ± SEM. * p<0.05 and & p=0.06 compared to Con, two-way ANOVA (factors: cohort and treatment) 
complemented with Bonferroni. Con: distilled water; P30: P. incarnata 30 mg/kg; P300: P. incarnata 300 mg/kg.
FIGURE 1 - Activation of human neutrophils by PMA in the 
absence (control) or presence of P. incarnata (5 or10 µL) or base 
syrup (10 µL). Each group was composed by 8-10 replicates. A. 
Kinetic curves obtained each other minute for 60 minutes. B. 
Box plot of the peak values from the kinetic curves. Data were 
analyzed by Kruskal-Wallis complemented with Dunn´s test. * 
p<0.05 compared to CON; # p<0.05 compared to base syrup.
DISCUSSION
In reproductive and developmental toxicity studies, 
evaluation of maternal toxicity is critical. This study was 
conducted according to the International Conference on 
Harmonization, Technical Requirements for Registration 
of Pharmaceuticals for Human Use guideline (ICH, 2005). 
The P. incarnata regimen of treatment adopted in the present 
study did not result in maternal toxicity as evidenced by the 
lack of effect on parameters of overt general toxicity (clinical 
signs, weight gain, general activity), hepatic function and 
reproductive performance. Literature lacks toxicological 
studies conducted in animals treated repeatedly with P. 
incarnata and none of the available monographs of P. 
incarnata mention results from these types of studies.
In this work, the antioxidant property of P. incarnata 
was evidenced both in vivo and in vitro. In vivo, there was 
a dose-dependent increase in TRAP which reflects both 
hydro and lipossoluble antioxidant substances (Repetto et 
al., 1996). In vitro, there was a decrease in PMA-induced 
respiratory burst in neutrophils, suggesting a scavenger 
activity of the syrup. In vitro antioxidant activity has also 
been described for aqueous and ethanolic extracts of P. 
incarnata in the DPPH (2.2-Diphenyl-1-picrylhydrazide) 
and ABTS (Azino-bis-(3-ethylbenzthiazoline-6-sulfonic 
acid) methods (Masteikova et al., 2008). Flavonoids 
have been described as the main phytoconstituents of 
P. incarnata (Raffaelli, Moneti, Toja, 1997) and the 
antioxidant activity of this species has been attributed to 
these molecules (Masteikova et al., 2008). Flavonoids are 
phenolic substances that can stabilize and delocalize the 
unpaired electron within its aromatic ring and are able to 
reduce free radical formation and to scavenge free radicals. 
Among the flavonoids that have been described in P. 
incarnata, vicenin, isovitexin and orentin have been shown 
to play a major role in the in vitro antiradical activity of this 
species (Masteikova et al., 2008). Moreover, in an in vivo 
study conducted with Wistar rats gavaged with vitexin and 
isovitexin, increased total antioxidant capacity has been 
described (Cao et al., 2011).
Although total plasmatic antioxidant potential was 
found to be increased in dams treated with P. incarnata, 
it was not observed a significant decrease in the plasmatic 
markers of oxidation, i.e., lipid hydroperoxides, MDA, 
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AOPP and NO. We cannot offer a definitive explanation 
for this observation but it could be hypothesized that 
an increased antioxidant capacity could be important to 
protect macromolecules from oxidation in the presence of 
oxidative stressors and not at baseline condition. Similar 
observation, i.e., increased TRAP in normal subjects in 
the absence of altered levels of lipid hydroperoxides, has 
also been described in a study from our group designed to 
evaluate the impact of green tea consumption in normal and 
dyslipidemic humans (Camargo, Daguer, Barbosa, 2006).
It is interesting to point out that, to our knowledge, 
this is the first study to describe in vivo antioxidant activity 
for P. incarnata. In the literature, decreased markers of 
oxidation have been described with other species from 
the Passiflora genus. P. edulis juice decreased levels of 
TBARS in the blood (reduced lipid peroxidation) of male 
rats treated for 28 days with 1,000mg/kg of the juice (De 
Souza et al., 2012). P. alata leaf extract (1 and 5 mg/kg, 
gavage, 30 days) prevented the increase of hepatic TBARS 
after a challenge with carbon tetrachloride in male rats 
(Rudnick et al., 2007).
In conclusion, the results from the present study 
indicate that P. incarnata treatment during gestation and 
lactation presents antioxidant activity in the absence of 
maternal reproductive toxicity.
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